ABSTRACT The sites of airway obstruction and dilatation after terbutaline administration were studied by inhalation imaging and pulmonary function tests in 12 stable asthmatic patients. Inhaled terbutaline as a therapeutic aerosol decreased airway resistance (Raw) and improved radioaerosol (Ae) images in nine, A V max50 in three, and xenon (Xe) images in five of 12 subjects, suggesting that its predominant site of action was on major airways. Subcutaneously injected terbutaline improved Raw, A V max50, and Ae images in 11 and Xe images in eight subjects indicating that it released bronchospasm in the major and minor airways. These findings in asthma suggest that aerosol and Xe imaging procedures are sensitive indicators of large and small airway obstruction respectively.
Inhalation lung imaging and pulmonary function tests were performed repeatedly in a young man for nearly a year after an acute inhalation exposure to ammonia (Taplin et al, 1976) . Aerosol images in this man showed excessive deposition in major airways and poor peripheral penetration. After inhalation of isoprenaline, the aerosol images reverted to near normal patterns whereas xenon (Xe) images remained unchanged. Similar findings were also obtained subsequently in a few other individuals with chronic obstructive pulmonary disease. These striking aerosol image changes suggested their possible value in determining the sites of obstruction in bronchial asthma and for showing the sites of action of inhaled and subcutaneously injected bronchodilator drugs.
Methods
Twelve stable (in remission) asthmatic patients aged 18 to 63 years with mild to severe airway obstruction, none of whom smoked cigarettes, were studied. The severity of asthma was graded on the basis of FEV1 values in percent of pre-'Supportedby Contract E (04-10) Gen-12 between US Energy Research and Development Agency and the University of California, Los Angeles. dicted; 70-80%=mild; 55-70=moderate, and <55=severe. Patients were not allowed sodium cromoglycate for at least 24 hours, an oral bronchodilator for at least 12 hours, or an inhaled bronchodilator for at least four hours before study. Subjects with acute respiratory infections during the previous month were excluded.
Baseline lung function tests (PFTs) and lung imaging procedures after inhaling 113Xe and aerosol (Ae) of 99'Technetium pertechnetate were performed in the morning of each of the three study days. After these procedures thie patients were treated in random double-blind fkshion with either (1) 1 ml of aerosolised terbutaline (0 5 mg) +0 5 ml saline subcutaneously (SC), (2) 1 ml aerosolised saline +0-5 ml terbutaline (0-25 mg) SC, or (3) 1 ml aerosolised saline +0-5 ml saline SC (placebo). Ten to 30 minutes after each treatment regimen, PFTs and lung imaging procedures were repeated for comparison with baseline findings. The protocol was approved by the UCLA Human Subject Protection Committee, and informed consent was obtained from each patient.
The subjects were evaluated with body plethysmography followed by maximal expiratory flow-volume (FV) curves performed with the subject breathing air and a low density gas (80% 493 Sawtantra K Chopra et al helium-20% oxygen mixture). Body plethysmographic measurements of airway resistance (Raw) and thoracic gas volume (Vtg) were performed using a 900 litre capacity box according to the method of Dubois et al (1956) . Specific airways conductance (sGaw= 1/Raw/Vtg) was calculated to correct for changes in Raw due to changes in Vtg. The average of five measurements was used. FV curves were performed using a rolling-seal spirometer (Cardiopulmonary Instrument Model 1220 with an x-y recorder, Hewlett-Packard Model 7041A). At least three FV curves were performed with the subject breathing air followed by three additional FV curves, each obtained after three inspiratory vital capacity breaths of 80% helium-20% oxygen, according to the technique described by Hutcheon et al (1974) . A V max50 was calculated as the difference in flow rates at 50% of the vital capacity between the helium and air FV curves; the method of matching the helium and air FV curves before and after bronchodilator treatment was similar to that described by Antic and Macklem (1976) .
Two inhalation lung imaging procedures were performed routinely. Xe lung images were obtained in the posterior projection after inhaling a single breath of 10 millicuries of '33Xe in one litre of oxygen, after rebreathing for eight to ten breaths, and then at 30-second intervals during Xe washout for at least three minutes while the patient breathed room air and exhaled into either a vented hood or a shielded 40 litre collection bag.
Radioaerosol lung imaging was performed with the patient in the upright position also in the posterior projection, and images were obtained immediately after inhalation and retention of about two millicuries of 99'Technetium pertechnetate (150 K counts/min/mCi). In place of an ultrasonic aerosol generator used in previous studies (Ramanna et al, 1975; Taplin et al, 1977b) , a plastic disposable positive pressure nebuliser* was used. This device when operated at a flow rate of about 10 1/min with either compressed air or oxygen, converts high specific activity pertechnetate solutions (10-15 mCi/ml) to a fine aerosol at the rate of 1 10 ml/min. A six litre plastic reservoir settling bag was placed in the inhalation line between the nebuliser and the patient's mouthpiece to remove large droplets (>2 '0 ,tm) from the aerosol (Hayes et al, 1979 (Taplin et al, 1977a There is excessive aerosol deposition in the regions of the major bronchi and only minimal aerosol is deposited throughout peripheral lung. After placebo treatment, the Ae image remained unchanged and sGaw showed less than 25% improvement. In the next set of images the abnormal baseline picture at the top shows moderately excessive deposition in the major bronchi and slight impairment of aerosol penetration to the lung periphery. After treatment, the image improved and showed only slight central deposition (+ or mild improvement in the Ae image). Similarly, FEV1 and sGaw also improved to a mild degree. The third set of images on the right of the pair just described were considered to indicate + + improvement. The moderately abnormal baseline image that exhibited excessive deposition in the trachea and the major airways (fig 4) represent the responses of three asthmatic patients with moderate to severe airway obstruction. The baseline Ae and Xe images in the top row show bilateral abnormalities. The Ae image shows excessive central deposition and regional reduction in peripheral penetration. The Xe rebreath image is likewise abnormal and shows diminished activity in both mid-lung regions. The washout image at 2-0 to 2 5 minutes shows slightly excessive retention in both mid-lung regions with greater retention on the right. After subcutaneous terbutaline, the aerosol and Xe rebreath and washout images in the middle row all reverted to entirely normal patterns. In contrast, after terbutaline inhalation, only the aerosol image changed to a near-normal pattern, whereas the Xe images remained abnormal. Thus Xe lung images were probably more sensitive indicators of small airway obstruction and dilatation whereas radioaerosol showed the sites and degrees of obstruction in the major airways not visible by Xe imaging.
INDIVIDUAL RESPONSE TO BRONCHODILATOR TREATMENT
The degree of improvement in airway function tests and in aerosol and Xe images after each treatment regimen (graded according to the criteria presented in table 1) is indicated in table 2 for each of the 12 asthmatic subjects studied. Despas et al (1970) . These abnormal image patterns reverted towards normal almost immediately after terbutaline treatment.
SUMMARY OF RESPONSES TO BRONCHODILATOR TREATMENT
The image changes coincided with improvement in sGaw (a measure of large airway function) and remained unaltered after the placebo regimen. Large airway obstruction in asthma is caused by reversible bronchospasm, excess mucus in the airways, and thickening of the bronchial wall by oedema and inflammation. These abnormalities promote excessive deposition of inhaled aerosol droplets in the large airways by gravitational sedimentation and turbulent impaction (Newhouse et al, 1976) . As a result, there is considerable reduction in the proportion of the total inhaled dose reaching and remaining in the terminal airways (<2 ,um) in normal subjects (Lippman and Albert, 1969; Albert et al, 1973) . The abnormal deposition tained with 133Xe which follows the airstream from the mouth to the alveoli without detectable deposition in the airways. When partial obstruction of small airways is present, however, regions distal to the obstruction become visible during the washout phase of the Xe examination as areas in which the gas is retained for longer periods than in the surrounding normally ventilated lung (Taplin et al, 1977b) . The abnormal Xe images were often reversible after bronchodilator treatment, and these changes showed fair agreement with improvement in A V max50, a measurement that probably reflects small airways resistance.
SITE OF ACTION OF TERBUTALINE
Controversy exists regarding the primary sites of airway obstruction in bronchial asthma (Despas et al, 1972; Mildon et al, 1974; Antic and Macklem, 1976; Chan-Yeung et al, 1976) . The relative effects of bronchodilator treatment on central and peripheral airway obstruction in asthma have not previously been studied in detail by aerosol and Xe imaging methods. The finding that Xe single-breath and washout images were relatively normal in some of the patients in the present study despite functional evidence and Ae image changes suggestive of central airway obstruction is consistent with the previous observations of others (Despas et al, 1972; Antic and Macklem, 1976) that the major site of obstruction is often located in central rather than peripheral airways. Inhaled terbutaline gave definite improvement in sGaw and Ae images only, whereas improvement in sGaw, A V max50, aerosol, and Xe images followed injected terbutaline (tables 3 and 4). These differences are probably related to the higher concentration of the aerosolised drug in the partially obstructed central bronchi than in the smaller peripheral airways. In patients with moderate to severe asthma inhaled aerosols of about 2 ,um deposit excessively in the central airways and relatively little is detectable in the peripheral lung. By contrast, in normal subjects, the same size aerosol reaches the terminal airways and alveoli where the bulk of the inhaled dose is deposited depending on its solubility. Therefore, assuming that the inhaled terbutaline as a therapeutic aerosol had about the same size and distribution in the major airways as the pertechnetate aerosol, it is reasonable to assume that its major effect was a topical one on the central airways. These findings also suggest that after an initial inhalation of terbutaline to relieve obstruction of the large airways, repeated inhalations might then permit more drug to reach the peripheral airways and relieve obstruction at these sites as well. This hypothesis warrants further study. The injected drug by its systemic action relieves obstruction affecting both the central and peripheral airways. 
